JP2023535598A5 - - Google Patents
Info
- Publication number
- JP2023535598A5 JP2023535598A5 JP2023505412A JP2023505412A JP2023535598A5 JP 2023535598 A5 JP2023535598 A5 JP 2023535598A5 JP 2023505412 A JP2023505412 A JP 2023505412A JP 2023505412 A JP2023505412 A JP 2023505412A JP 2023535598 A5 JP2023535598 A5 JP 2023535598A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010730899.8 | 2020-07-27 | ||
| CN202010730899 | 2020-07-27 | ||
| CN202010735910 | 2020-07-28 | ||
| CN202010735910.X | 2020-07-28 | ||
| PCT/CN2021/108666 WO2022022508A1 (zh) | 2020-07-27 | 2021-07-27 | 抗cd79b抗体药物偶联物、其制备方法及其医药用途 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023535598A JP2023535598A (ja) | 2023-08-18 |
| JPWO2022022508A5 JPWO2022022508A5 (https=) | 2024-08-27 |
| JP2023535598A5 true JP2023535598A5 (https=) | 2024-08-27 |
| JP7817236B2 JP7817236B2 (ja) | 2026-02-18 |
Family
ID=80037618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023505412A Active JP7817236B2 (ja) | 2020-07-27 | 2021-07-27 | 抗ｃｄ７９ｂ抗体薬物複合体、その調製方法及びその医薬用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230405138A1 (https=) |
| EP (1) | EP4190812A4 (https=) |
| JP (1) | JP7817236B2 (https=) |
| KR (1) | KR20230044275A (https=) |
| CN (1) | CN115698079A (https=) |
| AU (1) | AU2021317378A1 (https=) |
| BR (1) | BR112023001359A2 (https=) |
| CA (1) | CA3184724A1 (https=) |
| MX (1) | MX2023001163A (https=) |
| TW (1) | TWI888610B (https=) |
| WO (1) | WO2022022508A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022316425A1 (en) * | 2021-07-22 | 2024-02-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Drug conjugate of eribulin derivative |
| CN117881431A (zh) * | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
| CN117677400A (zh) * | 2021-09-16 | 2024-03-08 | 正大天晴药业集团股份有限公司 | 抗her3抗体药物偶联物及其组合物和用途 |
| EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| JP2025504419A (ja) * | 2022-01-26 | 2025-02-12 | 上▲海▼▲邁▼晋生物医▲薬▼科技有限公司 | 抗ＣＤ７９ｂ抗体薬物複合体を含む医薬組成物及びその使用 |
| CN118647408A (zh) * | 2022-02-16 | 2024-09-13 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
| AU2023225240A1 (en) * | 2022-02-24 | 2024-09-05 | Evopoint Biosciences Co., Ltd. | Antibody, and drug conjugate and use thereof |
| EP4568997A1 (en) * | 2022-08-08 | 2025-06-18 | ATB Therapeutics | Humanized antibodies against cd79b |
| KR20250084935A (ko) * | 2022-10-14 | 2025-06-11 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 링커-페이로드 화합물, 접합체 및 이의 응용 분야 |
| CN117917248A (zh) * | 2022-10-20 | 2024-04-23 | 英诺湖医药(杭州)有限公司 | 酶裂解连接子及包含其的配体-艾瑞布林偶联物 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| TWI894742B (zh) * | 2022-12-29 | 2025-08-21 | 美商Ｌｔｚ治療股份有限公司 | 抗CD79b抗體及其用途 |
| KR20250143351A (ko) * | 2023-04-12 | 2025-10-01 | 레메젠 코, 리미티드 | 모노메틸 아우리스타틴 e 화합물의 제조 및 정제 방법 |
| WO2025162492A1 (zh) * | 2024-01-29 | 2025-08-07 | 甘李药业股份有限公司 | 一种连接子、配体-药物偶联物及其医药用途 |
| WO2025162364A1 (zh) * | 2024-02-02 | 2025-08-07 | 江苏恒瑞医药股份有限公司 | 抗CD79b抗体药物偶联物联合免疫治疗剂、化疗剂治疗肿瘤 |
| WO2025209279A1 (zh) * | 2024-04-03 | 2025-10-09 | 英诺湖医药(杭州)有限公司 | 一种抗b7h3抗体-艾瑞布林偶联物及其应用 |
| WO2026006252A1 (en) * | 2024-06-25 | 2026-01-02 | Abbvie Inc. | Anti-cd79b antibody drug conjugates |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| AU2016273960B2 (en) * | 2007-07-16 | 2019-01-24 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
| NZ583318A (en) * | 2007-07-16 | 2012-07-27 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| SG187517A1 (en) * | 2008-01-31 | 2013-02-28 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| HRP20170374T1 (hr) | 2008-09-26 | 2017-05-05 | Ucb Biopharma Sprl | Biološki proizvodi |
| DK2992016T3 (en) * | 2013-05-02 | 2018-01-02 | Hoffmann La Roche | Combination therapy of an afucosylated CD20 antibody with a CD79b antibody-drug conjugate |
| PT3262071T (pt) * | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
| MA40938A (fr) * | 2014-12-05 | 2017-10-11 | Hoffmann La Roche | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps |
| KR20180115743A (ko) | 2016-02-26 | 2018-10-23 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 신규 독소, 및 이의 중간체를 제조하는 방법 |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
| WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CN112543771B (zh) | 2018-09-30 | 2023-04-11 | 江苏豪森药业集团有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
| CN111116745B (zh) * | 2018-11-01 | 2022-10-14 | 上海新理念生物医药科技有限公司 | 抗CD79b抗体、其药物偶联物及其应用 |
| BR112021014420A2 (pt) * | 2019-01-28 | 2021-09-21 | Tuojie Biotech (Shanghai) Co., Ltd. | Anticorpo anti-cd79b, fragmento de ligação ao antígeno do mesmo e uso farmacêutico do mesmo |
| CN118949063A (zh) * | 2020-01-22 | 2024-11-15 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
-
2021
- 2021-07-27 MX MX2023001163A patent/MX2023001163A/es unknown
- 2021-07-27 CA CA3184724A patent/CA3184724A1/en active Pending
- 2021-07-27 US US18/018,241 patent/US20230405138A1/en active Pending
- 2021-07-27 EP EP21849525.7A patent/EP4190812A4/en active Pending
- 2021-07-27 TW TW110127556A patent/TWI888610B/zh active
- 2021-07-27 BR BR112023001359A patent/BR112023001359A2/pt unknown
- 2021-07-27 JP JP2023505412A patent/JP7817236B2/ja active Active
- 2021-07-27 KR KR1020237006821A patent/KR20230044275A/ko active Pending
- 2021-07-27 CN CN202180042603.6A patent/CN115698079A/zh active Pending
- 2021-07-27 AU AU2021317378A patent/AU2021317378A1/en active Pending
- 2021-07-27 WO PCT/CN2021/108666 patent/WO2022022508A1/zh not_active Ceased